These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33745436)

  • 21. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perturbation Theory/Machine Learning Model of ChEMBL Data for Dopamine Targets: Docking, Synthesis, and Assay of New l-Prolyl-l-leucyl-glycinamide Peptidomimetics.
    Ferreira da Costa J; Silva D; Caamaño O; Brea JM; Loza MI; Munteanu CR; Pazos A; García-Mera X; González-Díaz H
    ACS Chem Neurosci; 2018 Nov; 9(11):2572-2587. PubMed ID: 29791132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute - Nanotechnology Characterization Laboratory.
    Caputo F; Mehn D; Clogston JD; Rösslein M; Prina-Mello A; Borgos SE; Gioria S; Calzolai L
    J Chromatogr A; 2021 Jan; 1635():461767. PubMed ID: 33310281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
    Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
    Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulating nanomedicine - can the FDA handle it?
    Bawa R
    Curr Drug Deliv; 2011 May; 8(3):227-34. PubMed ID: 21291376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EMEA and Gene Therapy Medicinal Products Development in the European Union.
    Papaluca Amati M; Pignatti F; Nolte A; Amerasinghe N; Gustafsson D; Moulon I; Le Courtois P
    J Biomed Biotechnol; 2003; 2003(1):3-8. PubMed ID: 12686717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of nanomedicines in the EU: distilling lessons from the pediatric and the advanced therapy medicinal products approaches.
    Chowdhury N
    Nanomedicine (Lond); 2010 Jan; 5(1):135-42. PubMed ID: 20025470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multioutput Perturbation-Theory Machine Learning (PTML) Model of ChEMBL Data for Antiretroviral Compounds.
    Vásquez-Domínguez E; Armijos-Jaramillo VD; Tejera E; González-Díaz H
    Mol Pharm; 2019 Oct; 16(10):4200-4212. PubMed ID: 31426639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PTML Model of ChEMBL Compounds Assays for Vitamin Derivatives.
    Santana R; Zuluaga R; Gañán P; Arrasate S; Onieva Caracuel E; González-Díaz H
    ACS Comb Sci; 2020 Mar; 22(3):129-141. PubMed ID: 32011854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
    Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
    Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Regulatory Landscape of New Health Technologies and Nanotechnologies: The Role of Complexity of Nanosystems.
    Naziris N; Demetzos C
    Adv Exp Med Biol; 2023; 1425():575-589. PubMed ID: 37581831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Data-driven modeling and prediction of blood glucose dynamics: Machine learning applications in type 1 diabetes.
    Woldaregay AZ; Årsand E; Walderhaug S; Albers D; Mamykina L; Botsis T; Hartvigsen G
    Artif Intell Med; 2019 Jul; 98():109-134. PubMed ID: 31383477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office.
    Dri DA; Gaucci E; Torrieri I; Carafa M; Marianecci C; Gramaglia D
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890333
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.